Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma

New criteria for response assessment: role of minimal residual disease in multiple myeloma

(2015) B. Paiva et al.   BLOOD

The development of potential antibody-based therapies for myeloma

(2015) Daniel W. Sherbenou et al.   BLOOD REVIEWS

Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of “normal” residual plasma cell analysis

(2015) Fanny Pojero et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

(2014) Ola Landgren et al.   AMERICAN JOURNAL OF HEMATOLOGY

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

(2014) J. Deckert et al.   CLINICAL CANCER RESEARCH

Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy

(2014) Stéphanie Mathis et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma

(2014) B. Paiva et al.   HAEMATOLOGICA

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

(2014) Murielle Roussel et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets

(2014) Nelly Robillard et al.   Frontiers in Immunology

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

(2013) A. Flanders et al.   BLOOD

CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma

(2013) André Veillette et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

CD38 and CD157: A long journey from activation markers to multifunctional molecules

(2013) Valeria Quarona et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

(2013) N Puig et al.   LEUKEMIA

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

(2013) E M Ocio et al.   LEUKEMIA

Overview of clinical flow cytometry data analysis: recent advances and future challenges

(2013) Carlos E. Pedreira et al.   TRENDS IN BIOTECHNOLOGY

A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma

(2013) N Robillard et al.   Blood Cancer Journal

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

(2012) Roger G. Owen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

(2012) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma

(2012) Dingsheng Liu et al.   JOURNAL OF CLINICAL PATHOLOGY

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

(2012) B Paiva et al.   LEUKEMIA

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

(2012) T Kalina et al.   LEUKEMIA

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

(2012) J J M van Dongen et al.   LEUKEMIA

FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma

(2012) K. Elkins et al.   MOLECULAR CANCER THERAPEUTICS

Diagnostic Usefulness and Prognostic Impact of CD200 Expression in Lymphoid Malignancies and Plasma Cell Myeloma

(2011) Daisy Alapat et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

(2011) B. Paiva et al.   BLOOD

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

(2011) J. A. Zonder et al.   BLOOD

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma

(2011) D. Atanackovic et al.   HAEMATOLOGICA

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

(2011) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Human peripheral blood B-cell compartments: A crossroad in B-cell traffic

(2010) M. Perez-Andres et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells

(2010) A. Caraux et al.   HAEMATOLOGICA

Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping

(2010) E S Costa et al.   LEUKEMIA

Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma

(2009) Ritu Gupta et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells

(2009) Y.-T. Tai et al.   BLOOD

Constitutively lower expressions of CD54 on primary myeloma cells and their different localizations in bone marrow

(2009) Mohd S. Iqbal et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease

(2009) E. Domingo et al.   HAEMATOLOGICA

Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients

(2008) S. Quijano et al.   BLOOD

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

(2008) B. Paiva et al.   BLOOD

Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach

(2008) Bridget E. McLaughlin et al.   CYTOMETRY PART A

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

(2008) A. C. Rawstron et al.   HAEMATOLOGICA

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

(2008) Gema Mateo et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

(2008) K Hatano et al.   ONCOGENE